Male Hypogonadism Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
세계 남성 성선기능저하증 시장 규모는 2025년 33억 달러에 달하고, 2025-2032년의 예측 기간 동안 4.6%의 연평균 복합 성장률(CAGR)로 확대되어 2032년에는 45억 달러에 달할 전망입니다.
남성 성선기능저하증 시장은 테스토스테론 수치 감소를 특징으로 하며 신체적, 정서적, 성적 건강 문제를 야기하는 질환의 진단과 치료에 초점을 맞추었습니다. 이 시장에는 테스토스테론 수치를 정상으로 되돌리고 증상을 완화하는 것을 목표로 하는 치료법이 포함됩니다. 성선기능저하증에 대한 인식 증가, 치료 옵션의 발전, 남성 인구의 고령화 등의 요인이 시장 성장의 원동력이 되고 있습니다. 성선기능저하증 관련 질환의 유병률 증가와 함께 연구개발에 대한 투자 확대는 시장 확대를 더욱 촉진하고 있습니다.
세계 남성 성선기능저하증 시장의 성장에는 생활습관의 변화와 고령화로 인한 테스토스테론 결핍증 유병률 증가 등 여러 가지 요인이 기여하고 있습니다. 진단 기술, 테스토스테론 대체요법, 성선자극호르몬 대체요법 등 치료법의 발전이 시장 수요를 견인하고 있습니다. 성선기능저하증과 삶의 질에 미치는 영향에 대한 인식이 높아짐에 따라 조기 진단 및 치료법 채택이 증가하고 있습니다. 신흥국의 의료 인프라 확대와 남성 건강에 대한 관심 증가는 시장 성장을 더욱 촉진하고 있습니다.
남성 성선기능저하증 시장은 치료 기술의 발전과 의료 서비스 접근성 확대로 인해 큰 성장 기회를 제공합니다. 지속형 주사제 및 경피 패치와 같은 약물 제제의 혁신은 시장 진출기업들에게 새로운 길을 열어주고 있습니다. 원격 의료와 디지털 건강 솔루션에 대한 관심이 높아지면서 진단과 치료 접근성이 향상되고 있습니다. 제약회사와 의료 서비스 제공업체의 전략적 제휴는 제품 개발을 가속화하고 시장 개척을 확대할 수 있습니다.
이 보고서는 세계 남성 성선기능저하증 시장을 조사했으며, 치료별/약물별/질병 유형별/지역별 동향, 시장 진출기업 프로파일 등의 정보를 제공합니다.
목차
제1장 세계 경제 전망
제2장 세계의 남성 성선기능저하증 시장-주요 요약
제3장 세계의 남성 성선기능저하증 시장 개요
제4장 세계의 남성 성선기능저하증 시장 분석과 예측, 2025년-2032년
- 세계의 남성 성선 기능 저하증 시장 규모와 예측, 2025년-2032년, 치료별
- 세계의 남성 성선 기능 저하증 시장 규모와 예측, 2025년-2032년, 약제 유형별
- 세계의 남성 성선 기능 저하증 시장 규모와 예측, 2025년-2032년, 질환 유형별
제5장 북미의 남성 성선 기능 저하증 시장 규모와 예측, 2025년-2032년
제6장 라틴아메리카의 남성 성선 기능 저하증 시장 규모와 예측, 2025년-2032년
제7장 유럽의 남성 성선 기능 저하증 시장 규모와 예측, 2025년-2032년
제8장 일본의 남성 성선 기능 저하증 시장 규모와 예측, 2025년-2032년
제9장 아시아태평양(일본 제외)의 남성 성선 기능 저하증 시장 규모와 예측, 2025년-2032년
제10장 중동 및 아프리카의 남성 성선 기능 저하증 시장 규모와 예측, 2025년-2032년
제11장 세계의 남성 성선기능저하증 시장 기업 점유율, 경쟁 구도, 기업 개요
- 기업 점유율 분석
- 경쟁 구도
- 기업 개요
- Endo International Plc
- Eli Lilly and Company Ltd.
- AbbVie, Inc.
- Pfizer, Inc.
- Merck KGaA
- Allergan Plc
- Sun Pharmaceutical Industries Limited
- Ferring B.V.
제12장 조사 방법
제13장 2차 자료와 1차 정보
제14장 가정과 두자어
제15장 면책사항
LSH
Persistence Market Research has recently released a comprehensive report on the global Male Hypogonadism Market, providing an in-depth analysis of key market dynamics, including drivers, emerging trends, opportunities, and challenges. This report delivers detailed insights into the market landscape, enabling stakeholders to make informed decisions.
Key Insights:
- Male Hypogonadism Market Size (2025E): USD 3.3 Bn
- Projected Market Value (2032F): USD 4.5 Bn
- Global Market Growth Rate (CAGR 2025 to 2032): 4.6%
Male Hypogonadism Market - Report Scope:
The Male Hypogonadism market focuses on the diagnosis and treatment of a condition characterized by low testosterone levels, leading to physical, emotional, and sexual health challenges. The market includes therapies aimed at restoring normal testosterone levels and alleviating symptoms. Factors such as increasing awareness of hypogonadism, advancements in therapeutic options, and an aging male population drive market growth. Growing investments in research and development, coupled with the rising prevalence of hypogonadism-related conditions, further propel market expansion.
Market Growth Drivers:
Several factors contribute to the growth of the global Male Hypogonadism market, including increasing prevalence of testosterone deficiency due to lifestyle changes and aging. Advancements in diagnostic technologies and therapies, such as testosterone replacement therapy and gonadotropin replacement therapy, are bolstering market demand. Rising awareness of hypogonadism and its effects on quality of life is also driving early diagnosis and treatment adoption. The expansion of healthcare infrastructure and increased focus on men's health in emerging economies further support market growth.
Market Restraints:
Despite its growth potential, the Male Hypogonadism market faces several challenges, including the risk of side effects associated with testosterone replacement therapies and stringent regulatory requirements for drug approvals. The stigma around discussing men's health issues and low awareness in developing regions hinder market penetration. High costs of advanced therapies and limited availability of treatment options in remote areas also pose significant barriers.
Market Opportunities:
The Male Hypogonadism market offers substantial growth opportunities driven by advancements in therapeutic technologies and expanding healthcare accessibility. Innovations in drug formulations, such as long-acting injectables and transdermal patches, create new avenues for market players. The increasing focus on telemedicine and digital health solutions also enhances diagnosis and treatment access. Strategic collaborations between pharmaceutical companies and healthcare providers can accelerate product development and expand market reach.
Key Questions Answered in the Report:
- What are the primary factors driving the global Male Hypogonadism market?
- Which therapies and drug types are witnessing the highest adoption?
- How are advancements in diagnostic and therapeutic technologies shaping the market?
- Who are the leading players in the Male Hypogonadism market, and what strategies are they employing to stay competitive?
- What are the emerging trends and future prospects for the global Male Hypogonadism market?
Competitive Intelligence and Business Strategy:
Leading companies in the global Male Hypogonadism market, such as Endo International Plc, Eli Lilly and Company Ltd., and Pfizer, Inc., are focusing on product innovation, research, and development to strengthen their market position. These companies are leveraging advancements in drug delivery technologies and expanding their portfolio to include a variety of therapies for hypogonadism. Strategic partnerships with healthcare institutions, regulatory bodies, and distributors enhance market penetration. Emphasizing patient education and awareness campaigns is a key strategy for driving adoption and long-term success.
Key Companies Profiled:
- Endo International Plc
- Eli Lilly and Company Ltd.
- AbbVie, Inc.
- Pfizer, Inc.
- Merck KGaA
- Allergan Plc
- Sun Pharmaceutical Industries Limited
- Ferring B.V.
- Others
Male Hypogonadism Industry Research by Category:
By Therapy:
- Testosterone Replacement Therapy
- Gonadotropin Replacement Therapy
By Drug Type:
- Topical Gels
- Injectables
- Transdermal Patches
- Others
By Disease Type:
- Klinefelter's Syndrome
- Pituitary Adenomas
- Kallmann Syndrome
- Other Types
By Region:
- North America
- Latin America
- Europe
- Japan
- APEJ
- MEA
Table of Contents
1. Global Economic Outlook
2. Global Male Hypogonadism Market - Executive Summary
- 2.1. Opportunity Analysis - Male Hypogonadism Market
3. Global Male Hypogonadism Market Overview
- 3.1. Introduction
- 3.1.1. Global Male Hypogonadism Market Taxonomy
- 3.1.2. Global Male Hypogonadism Market Definition
- 3.2. Global Male Hypogonadism Market Size (US$ Bn ) and Forecast, 2025 - 2032
- 3.2.1. Global Male Hypogonadism Market Y-o-Y Growth
- 3.3. Global Male Hypogonadism Market Dynamics
- 3.4. Supply Chain
- 3.5. Cost Structure
- 3.6. Pricing Analysis
- 3.7. PESTL Analysis
- 3.8. Product Life Cycle Analysis
- 3.9. Epidemiology
- 3.10. List of Distributors
- 3.11. Key Participants Market Presence (Intensity Map) By Region
4. Global Male Hypogonadism Market Analysis and Forecast 2025 - 2032
- 4.1. Global Male Hypogonadism Market Size and Forecast By Therapy , 2025 - 2032
- 4.1.1. Testosterone Replacement Therapy Market Size and Forecast, 2025 - 2032
- 4.1.1.1. Revenue (US$ Bn ) Comparison, By Region
- 4.1.1.2. Market Share Comparison, By Region
- 4.1.1.3. Y-o-Y growth Comparison, By Region
- 4.1.2. Gonadotropin Replacement Therapy Market Size and Forecast, 2025 - 2032
- 4.1.2.1. Revenue (US$ Bn ) Comparison, By Region
- 4.1.2.2. Market Share Comparison, By Region
- 4.1.2.3. Y-o-Y growth Comparison, By Region
- 4.2. Global Male Hypogonadism Market Size and Forecast By Drug Type, 2025 - 2032
- 4.2.1. Topical Gels Market Size and Forecast, 2025 - 2032
- 4.2.1.1. Revenue (US$ Bn ) Comparison, By Region
- 4.2.1.2. Market Share Comparison, By Region
- 4.2.1.3. Y-o-Y growth Comparison, By Region
- 4.2.2. Injectables Market Size and Forecast, 2025 - 2032
- 4.2.2.1. Revenue (US$ Bn ) Comparison, By Region
- 4.2.2.2. Market Share Comparison, By Region
- 4.2.2.3. Y-o-Y growth Comparison, By Region
- 4.2.3. Transdermal Patches Market Size and Forecast, 2025 - 2032
- 4.2.3.1. Revenue (US$ Bn ) Comparison, By Region
- 4.2.3.2. Market Share Comparison, By Region
- 4.2.3.3. Y-o-Y growth Comparison, By Region
- 4.2.4. Others Market Size and Forecast, 2025 - 2032
- 4.2.4.1. Revenue (US$ Bn ) Comparison, By Region
- 4.2.4.2. Market Share Comparison, By Region
- 4.2.4.3. Y-o-Y growth Comparison, By Region
- 4.3. Global Male Hypogonadism Market Size and Forecast By Disease Type, 2025 - 2032
- 4.3.1. Klinefelter's Syndrome Market Size and Forecast, 2025 - 2032
- 4.3.1.1. Revenue (US$ Bn ) Comparison, By Region
- 4.3.1.2. Market Share Comparison, By Region
- 4.3.1.3. Y-o-Y growth Comparison, By Region
- 4.3.2. Pituitary Adenomas Market Size and Forecast, 2025 - 2032
- 4.3.2.1. Revenue (US$ Bn ) Comparison, By Region
- 4.3.2.2. Market Share Comparison, By Region
- 4.3.2.3. Y-o-Y growth Comparison, By Region
- 4.3.3. Kallmann Syndrome Market Size and Forecast, 2025 - 2032
- 4.3.3.1. Revenue (US$ Bn ) Comparison, By Region
- 4.3.3.2. Market Share Comparison, By Region
- 4.3.3.3. Y-o-Y growth Comparison, By Region
- 4.3.4. Other Types Market Size and Forecast, 2025 - 2032
- 4.3.4.1. Revenue (US$ Bn ) Comparison, By Region
- 4.3.4.2. Market Share Comparison, By Region
- 4.3.4.3. Y-o-Y growth Comparison, By Region
5. North America Male Hypogonadism Market Size and Forecast, 2025 - 2032
- 5.1. North America Outlook
- 5.2. North America Parent Market Outlook
- 5.3. North America Target Market Outlook
- 5.4. Revenue (US$ Bn ) Comparison, By Country
- 5.4.1. US Market Size and Forecast (US$ Bn ), 2025 - 2032
- 5.4.2. Canada Market Size and Forecast (US$ Bn ), 2025 - 2032
- 5.5. Revenue (US$ Bn ) Comparison, By Therapy
- 5.6. Revenue (US$ Bn ) Comparison, By Drug Type
- 5.7. Revenue (US$ Bn ) Comparison, By Disease Type
6. Latin America Male Hypogonadism Market Size and Forecast, 2025 - 2032
- 6.1. Latin America Outlook
- 6.2. Latin America Parent Market Outlook
- 6.3. Latin America Target Market Outlook
- 6.4. Revenue (US$ Bn ) Comparison, By Country
- 6.4.1. Brazil Market Size and Forecast (US$ Bn ), 2025 - 2032
- 6.4.2. Mexico Market Size and Forecast (US$ Bn ), 2025 - 2032
- 6.4.3. Rest of Latin America Market Size and Forecast (US$ Bn ), 2025 - 2032
- 6.5. Revenue (US$ Bn ) Comparison, By Therapy
- 6.6. Revenue (US$ Bn ) Comparison, By Drug Type
- 6.7. Revenue (US$ Bn ) Comparison, By Disease Type
7. Europe Male Hypogonadism Market Size and Forecast, 2025 - 2032
- 7.1. Europe Outlook
- 7.2. Europe Parent Market Outlook
- 7.3. Europe Target Market Outlook
- 7.4. Revenue (US$ Bn ) Comparison, By Country
- 7.4.1. Germany Market Size and Forecast (US$ Bn ), 2025 - 2032
- 7.4.2. UK Market Size and Forecast (US$ Bn ), 2025 - 2032
- 7.4.3. France Market Size and Forecast (US$ Bn ), 2025 - 2032
- 7.4.4. Spain Market Size and Forecast (US$ Bn ), 2025 - 2032
- 7.4.5. Italy Market Size and Forecast (US$ Bn ), 2025 - 2032
- 7.4.6. Rest of Europe Market Size and Forecast (US$ Bn ), 2025 - 2032
- 7.5. Revenue (US$ Bn ) Comparison, By Therapy
- 7.6. Revenue (US$ Bn ) Comparison, By Drug Type
- 7.7. Revenue (US$ Bn ) Comparison, By Disease Type
8. Japan Male Hypogonadism Market Size and Forecast, 2025 - 2032
- 8.1. Japan Outlook
- 8.2. Japan Parent Market Outlook
- 8.3. Japan Target Market Outlook
- 8.4. Revenue (US$ Bn ), 2025 - 2032
- 8.4.1. Japan Market Size and Forecast (US$ Bn ), 2025 - 2032
- 8.5. Revenue (US$ Bn ) Comparison, By Therapy
- 8.6. Revenue (US$ Bn ) Comparison, By Drug Type
- 8.7. Revenue (US$ Bn ) Comparison, By Disease Type
9. APEJ Male Hypogonadism Market Size and Forecast, 2025 - 2032
- 9.1. APEJ Outlook
- 9.2. APEJ Parent Market Outlook
- 9.3. APEJ Target Market Outlook
- 9.4. Revenue (US$ Bn ) Comparison, By Country
- 9.4.1. China Market Size and Forecast (US$ Bn ), 2025 - 2032
- 9.4.2. India Market Size and Forecast (US$ Bn ), 2025 - 2032
- 9.4.3. Thailand Market Size and Forecast (US$ Bn ), 2025 - 2032
- 9.4.4. Singapore Market Size and Forecast (US$ Bn ), 2025 - 2032
- 9.4.5. Australia Market Size and Forecast (US$ Bn ), 2025 - 2032
- 9.4.6. Rest of APEJ Market Size and Forecast (US$ Bn ), 2025 - 2032
- 9.5. Revenue (US$ Bn ) Comparison, By Therapy
- 9.6. Revenue (US$ Bn ) Comparison, By Drug Type
- 9.7. Revenue (US$ Bn ) Comparison, By Disease Type
10. MEA Male Hypogonadism Market Size and Forecast, 2025 - 2032
- 10.1. MEA Outlook
- 10.2. MEA Parent Market Outlook
- 10.3. MEA Target Market Outlook
- 10.4. Revenue (US$ Bn ) Comparison, By Country
- 10.4.1. GCC Countries Market Size and Forecast (US$ Bn ), 2025 - 2032
- 10.4.2. South Africa Market Size and Forecast (US$ Bn ), 2025 - 2032
- 10.4.3. Israel Market Size and Forecast (US$ Bn ), 2025 - 2032
- 10.4.4. Rest of MEA Market Size and Forecast (US$ Bn ), 2025 - 2032
- 10.5. Revenue (US$ Bn ) Comparison, By Therapy
- 10.6. Revenue (US$ Bn ) Comparison, By Drug Type
- 10.7. Revenue (US$ Bn ) Comparison, By Disease Type
11. Global Male Hypogonadism Market Company Share, Competition Landscape and Company Profiles
- 11.1. Company Share Analysis
- 11.2. Competition Landscape
- 11.3. Company Profiles
- 11.3.1. Endo International Plc
- 11.3.2. Eli Lilly and Company Ltd.
- 11.3.3. AbbVie, Inc.
- 11.3.4. Pfizer, Inc.
- 11.3.5. Merck KGaA
- 11.3.6. Allergan Plc
- 11.3.7. Sun Pharmaceutical Industries Limited
- 11.3.8. Ferring B.V.
- 11.4. Key takeaways - Male Hypogonadism Market
12. Research Methodology
13. Secondary and Primary Sources
14. Assumptions and Acronyms
15. Disclaimer
